MOST POPULAR

Details emerge of first Huntington’s disease gene therapy clinical trial

UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein...

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of...

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for...

PEOPLE

LIFE

DESIGN

217,682FansLike
66,395FollowersFollow
24,215SubscribersSubscribe

LATEST VIDEOS

TECH POPULAR

TRAVEL

A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for...

Abstract Huntington’s disease (HD) is a devastating, genetic neurodegenerative disease caused by a tri-nucleotide expansion in exon 1 of the huntingtin gene. HD is clinically...
0 Condivisioni